sellWeak cluster of 210b5-1 plan
Amy L. Burroughs sold $2.5M of TERN
Chief Executive Officer at Terns Pharmaceuticals, Inc.. 68,749 shares at an average of $37.07, traded Jan 15, 2026, filed Jan 16, 2026.
Warning score
28Value
$2.5M
68,749 shares
Holdings after
288,976
-19% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$2.5M at market
- +5Share of holdings soldSold 19% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001872564-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 14, 2026 | AGrant or award Common Stock10b5-1 | +150,000 | $0.00 | $0 | 288,976 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Common Stock10b5-1 | +27,083 | $4.64 | $126k | 316,059 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Common Stock10b5-1 | +27,083 | $4.64 | $126k | 343,142 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Common Stock10b5-1 | +14,583 | $4.64 | $68k | 357,725 | Jan 16, 2026 |
| Jan 15, 2026 | SOpen-market sale Common Stock10b5-1 | -61,228 | $37.02 | $2.3M | 296,497 | Jan 16, 2026 |
| Jan 15, 2026 | SOpen-market sale Common Stock10b5-1 | -7,521 | $37.53 | $282k | 288,976 | Jan 16, 2026 |
| Jan 14, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +300,000 | $0.00 | $0 | 300,000 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,083 | $0.00 | $0 | 1,026,366 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,083 | $0.00 | $0 | 999,283 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,583 | $0.00 | $0 | 984,700 | Jan 16, 2026 |
Related signals
Other insiders at Terns Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $50k 942 shares | -1% | |
| 11Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $681k 14,583 shares | -5% | |
| 9Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $572k 14,583 shares | -5% | |
| 53Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $2.7M 71,339 shares | -34% | |
| 29Weak | Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $45k 1,155 shares | -2% | |
| 17Weak | Terns Pharmaceuticals, Inc. | Jill M. Quigley Sr. Advisor & Strategy Officer | $441k 24,520 shares | -100% | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $7,407 944 shares | -2% | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $3,640 853 shares | -2% | |
| 51Moderate | Terns Pharmaceuticals, Inc. | Andrew Gengos Chief Financial Officer | $39k 10,000 shares | +67% | |
| 52Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $90k 23,314 shares | +98% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.